# A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

> **NCT06345755** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 159 (actual)

## Conditions studied

- Autosomal Dominant Polycystic Kidney Disease (ADPKD)

## Interventions

- **DRUG:** VX-407
- **DRUG:** Placebo
- **DRUG:** Midazolam
- **DRUG:** VX-407

## Key facts

- **NCT ID:** NCT06345755
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-17
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-06-13
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06345755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06345755, "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06345755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*